Eosinophilic granulomatosis with polyangiitis: recent therapeutic advances - PubMed
10 hours ago
- #treatment advances
- #biologics
- #EGPA
- Recent advances in treatment options for eosinophilic granulomatosis with polyangiitis (EGPA) were reviewed.
- The MANDARA trial showed benralizumab's noninferiority to mepolizumab for inducing remission in EGPA patients.
- Real-world studies have supported the findings of the MANDARA trial.
- A randomized controlled trial found rituximab non-superior to standard therapy for inducing remission in EGPA.
- Targeting other molecular pathways showed limited effectiveness in controlling EGPA's systemic manifestations.
- Cases of EGPA onset were reported in severe asthma patients treated with monoclonal antibodies.
- IL-5 targeting biologics are now central to EGPA treatment, though their role in remission induction needs further study.
- Future guidelines should incorporate these findings to enhance EGPA management.